Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).
Details for the oral presentation are as follows:
Session Title:
Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies – Take 1
Session Date/Time:
Saturday, June 21, 2025, 4:30 PM - 6:00 PM CDT
Presentation Title:
Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight
Presenter:
John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune
Presentation Date/Time:
Saturday, June 21, 2025 at 5:45 PM CDT
Details of the poster presentations are as follows:
Title:
Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment (poster #749-P)
Non-invasive Tests of Central Adiposity Correlate with Reductions in MRI-measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide (poster #748-P)
Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model (poster #778-P)
Presenter:
John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune
Presentation Date/Time:
Sunday, June 22, 2025, 12:30PM - 1:30 PM CDT
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Write a comment
000
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
分享到weixin
分享到qq
分享到facebook
分享到twitter
分享到微博
粘贴板
Use the share button in your browser to share the page with your friends
